Peptide purification by reverse-phase HPLC

Reverse-phase HPLC separates molecules by their hydrophobicity. The stationary phase is a non-polar bonded silica (most commonly C18, sometimes C8 or C4 for larger peptides), and the mobile phase is a gradient that starts mostly aqueous and ramps toward an organic solvent — usually acetonitrile, occasionally methanol or isopropanol. As the percentage of organic increases, hydrophobic species are pulled off the column and detected as they elute.

Peptides are well-suited to RP-HPLC for two reasons. First, the hydrophobicity of a peptide is the sum of its residues, which means a single amino acid difference (a deletion, a truncation, an oxidation) usually shifts the retention time enough to physically separate. Second, the standard mobile phases — water, acetonitrile, and a volatile ion-pairing acid like trifluoroacetic acid (TFA) or formic acid — can be removed quantitatively by lyophilization, leaving a solid peptide product.

A purification campaign starts on a small analytical column (typically 4.6 × 150 mm, 5 µm C18). A few microliters of dissolved crude is injected with a broad scouting gradient — for example, 5% to 95% acetonitrile in 0.1% TFA over 30 minutes — to find where the target peak elutes and to map every nearby impurity.

Once the target retention time is known, the gradient is narrowed and shallowed to maximize selectivity around it. Halving the gradient slope often doubles the separation between the target and the closest impurity, at the cost of doubling the run time. Method development typically takes a day or two of analytical work before any preparative injection.

Preparative columns are larger in every dimension — 20 to 100+ mm internal diameter, 10 to 15 µm particles, 100 to 500 mm length. Scaling a method from analytical to preparative requires holding three things constant: linear velocity (cm/min), gradient slope (% organic per column volume), and mass loading per gram of stationary phase. With those held constant, the chromatography looks the same on both columns.

Loading is typically 5 to 20 mg of crude per gram of preparative stationary phase. Overloading the column compresses peaks together and erodes the very selectivity that was developed analytically — one of the most common reasons a purification yields a low-purity product despite a beautifully developed analytical method.

As the gradient elutes the loaded column, a fraction collector slices the eluent into time-based aliquots. Every fraction across the target peak window is collected, and each is subsequently analyzed by analytical HPLC and LC-MS to confirm what it actually contains.

Only fractions that meet the purity specification (typically ≥95%, often ≥98% for clinical-grade material) are pooled. Edge fractions where the target overlaps an early- or late-eluting impurity are sometimes set aside for re-purification rather than thrown away.

The pooled fractions are diluted with water (to reduce the organic content), frozen, and lyophilized. The result is a fluffy, low-density powder that is, at this point, the TFA salt of the peptide.

Trifluoroacetate is a strong ion-pair, which is why TFA is the dominant additive in peptide RP-HPLC. But TFA is cytotoxic at high levels, biologically active even at trace levels, and it interferes with downstream cell-based assays. For most end uses, the TFA counter-ion must be exchanged for something more neutral — commonly acetate, sometimes hydrochloride, occasionally a fully neutralized free base.

Counter-ion exchange is typically done by either (a) running a second HPLC purification in a different ion-pairing acid (e.g., 0.1% acetic acid or dilute HCl) or (b) passing the dissolved peptide through an ion-exchange resin in the desired counter-ion form. The peptide is then re-lyophilized.

Counter-ion content is rarely visible to end users, but it directly affects how much actual peptide is in a labeled vial. A vial labeled "5 mg of peptide" that is, in fact, a 15% TFA salt contains roughly 4.25 mg of peptide and 0.75 mg of trifluoroacetate. This is why a separate quantitative content assay (typically by amino acid analysis, UV at 280 nm, or HPLC against a calibrated reference) is needed alongside the purity number.

Even excellent preparative HPLC cannot separate co-eluting species. The most common offenders are:

• Single-residue deletions of a hydrophobically neutral residue (Gly, Ala) often co-elute with the target and require orthogonal separation modes to remove.
• D-isomers from racemization have identical mass and very similar hydrophobicity; chiral HPLC or specialized chromatography is needed to detect them.
• Iso-aspartate / aspartimide byproducts can co-elute and require LC-MS/MS or NMR to distinguish.

These are the categories of impurity that an honest analytical lab looks for explicitly — not just a single purity number on a chromatogram. And for recombinant proteins like somatropin, preparative RP-HPLC is only one axis of purification: covalent dimers and non-covalent aggregates require a stability-indicating SEC-HPLC step, and residual host-cell protein requires a strain-matched HCP ELISA that no chromatographic method substitutes for.